Systemic inflammatory markers and serum lactate dehydrogenase predict survival in patients with Wilms tumour.

Wilms tumour lactate dehydrogenase neutrophils paediatric systemic inflammation

Journal

Archives of medical science : AMS
ISSN: 1734-1922
Titre abrégé: Arch Med Sci
Pays: Poland
ID NLM: 101258257

Informations de publication

Date de publication:
2022
Historique:
received: 16 04 2020
accepted: 19 07 2020
entrez: 26 9 2022
pubmed: 18 4 2021
medline: 18 4 2021
Statut: epublish

Résumé

Markers of inflammation such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) have been found to be associated with survival in cancer patients. The aim of the current study was to establish the prognostic significance of simple laboratory markers of systemic inflammation in paediatric patients diagnosed with Wilms tumour (WT). Additionally, we aimed to compare the complete blood count (CBC) parameters of WT patients and the non-oncological control group. The study group included 88 children diagnosed with WT. Clinicopathological data, as well as CBC, C-reactive protein (CRP) and lactate dehydrogenase (LDH) levels at diagnosis, were obtained. Additionally, the laboratory results of 62 healthy control paediatric patients were collected. Uni- and multivariate proportional Cox's hazard analyses were computed to create a model predicting relapse-free survival (RFS) and overall survival (OS) in the study group. High CRP, LDH, and NLR were associated with a higher stage of WT and shorter RFS, whereas all parameters correlated with OS. In multivariate analysis, only LDH levels had adverse significance in predicting RFS. C-reactive protein and LMR retained their prognostic value in the multivariate model predicting OS. Comparing the WT group with controls, high LDH, high CRP, high NLR, and high PLR were associated with WT presence. Preoperative LDH, CRP, NLR, PLR, and LMR have significant prognostic value in patients with WT independently of age and stage. Combined low CRP and high LMR identified the group of patients with excellent OS. Patients with high LDH were characterized by the highest risk of relapse.

Identifiants

pubmed: 36160344
doi: 10.5114/aoms/125543
pii: 125543
pmc: PMC9479718
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1253-1261

Informations de copyright

Copyright: © 2021 Termedia & Banach.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
Ann Surg Oncol. 2017 Oct;24(11):3456-3462
pubmed: 28718035
Cancer Res. 2009 Jul 1;69(13):5383-91
pubmed: 19549917
Cancer Epidemiol. 2019 Apr;59:71-74
pubmed: 30703618
J Cancer Res Clin Oncol. 2010 Feb;136(2):293-305
pubmed: 19693535
PLoS One. 2019 Aug 19;14(8):e0221373
pubmed: 31425556
Mol Clin Oncol. 2016 Dec;5(6):832-838
pubmed: 28105365
Neoplasia. 2017 Mar;19(3):237-249
pubmed: 28254151
J Pediatr Hematol Oncol. 2017 Oct;39(7):538-546
pubmed: 28697168
J Oncol. 2019 Aug 29;2019:2476082
pubmed: 31558903
Transl Pediatr. 2015 Jan;4(1):20-32
pubmed: 26835356
Int Braz J Urol. 2016 Jan-Feb;42(1):53-9
pubmed: 27136467
Scand J Immunol. 2009 Nov;70(5):490-500
pubmed: 19874554
Transl Oncol. 2014 Aug;7(4):484-92
pubmed: 24969538
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Medicine (Baltimore). 2018 Jun;97(23):e10831
pubmed: 29879017
Genes Dev. 2018 Oct 1;32(19-20):1267-1284
pubmed: 30275043
Int J Biol Markers. 2011 Oct-Dec;26(4):209-15
pubmed: 22139643
Int J Surg. 2018 May;53:304-311
pubmed: 29654963
Cancer Med. 2019 Aug;8(9):4135-4148
pubmed: 31197958
Lung Cancer. 2017 Sep;111:176-181
pubmed: 28838390
Oncotarget. 2017 Jun 19;8(40):68837-68846
pubmed: 28978160
Pediatr Hematol Oncol. 2009 Sep;26(6):407-13
pubmed: 19657990
Int Surg. 2015 Feb;100(2):199-207
pubmed: 25692418
Br J Urol. 1997 Oct;80(4):670-1
pubmed: 9352713
Surg Today. 2018 Nov;48(11):986-993
pubmed: 29946884
Cancer. 1985 Jul 1;56(1):178-81
pubmed: 4005788
J Pediatr Hematol Oncol. 2016 May;38(4):e147-50
pubmed: 26989912
Clin Biochem. 2001 Sep;34(6):441-54
pubmed: 11676973
Int Urol Nephrol. 2017 Jun;49(6):967-974
pubmed: 28247169
Paediatr Drugs. 2019 Feb;21(1):1-13
pubmed: 30604241
Asian J Androl. 2014 May-Jun;16(3):467-71
pubmed: 24589465
J Clin Oncol. 2004 Apr 15;22(8):1366-72
pubmed: 15084612
Arch Med Sci. 2019 Sep 09;17(6):1672-1678
pubmed: 34900048
Springerplus. 2014 May 12;3:243
pubmed: 24877032
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Sci Rep. 2017 Mar 27;7:45194
pubmed: 28345594
Front Pediatr. 2019 May 24;7:207
pubmed: 31179256
Onco Targets Ther. 2012;5:417-23
pubmed: 23226699
Front Oncol. 2019 Apr 30;9:327
pubmed: 31114757

Auteurs

Michał Kunc (M)

Department of Pathomorphology, Medical University of Gdansk, Gdansk, Poland.

Anna Gabrych (A)

Department of Pediatrics, Hematology and Oncology, Medical University of Gdansk, Gdansk, Poland.

Dominika Dulak (D)

The English Division Pediatric Oncology Scientific Circle, Medical University of Gdansk, Gdansk, Poland.

Karolina Hasko (K)

The English Division Pediatric Oncology Scientific Circle, Medical University of Gdansk, Gdansk, Poland.

Malgorzata Styczewska (M)

The English Division Pediatric Oncology Scientific Circle, Medical University of Gdansk, Gdansk, Poland.

Dagmara Szmyd (D)

Coronary Care Unit, Cardiology Department, West Cumberland Hospital, Whitehaven, United Kingdom.

Kristoffer Nilsson (K)

The English Division Pediatric Oncology Scientific Circle, Medical University of Gdansk, Gdansk, Poland.

Marek Iwinski (M)

The English Division Pediatric Oncology Scientific Circle, Medical University of Gdansk, Gdansk, Poland.

Agata Sobocińska-Mirska (A)

Department of Pediatrics, Oncology and Hematology, Medical University of Warsaw, Warsaw, Poland.

Malgorzata Sawicka-Zukowska (M)

Department of Pediatrics, Paediatric Oncology, and Hematology, Medical University of Bialystok, Bialystok, Poland.

Malgorzata A Krawczyk (MA)

Department of Pediatrics, Hematology and Oncology, Medical University of Gdansk, Gdansk, Poland.

Ewa Bien (E)

Department of Pediatrics, Hematology and Oncology, Medical University of Gdansk, Gdansk, Poland.

Classifications MeSH